
11.00	Coffee break		
11.30	Drug development of reversible covalently interacting protease inhibitors by means of QM, QM/MM and QM/MM MD Bernd Engels, Würzburg		
11.55	Structural studies and inhibition of human furin Manuel Than, Jena		
12.20	Proteomic analysis of cellular proteolysis: Biomedical applications Oliver Schilling, Freiburg		
12.45	It's make or break: Meprin metalloproteases induce collagen assembly in fibrosis metalloproteases Christoph Becker-Pauly, Kiel		
13.10	Lunch		
14.00	Bioactive natural products from sponge-associated actinomycetes Usama Ramadan Abdelmohsen, Würzburg		
	Bioactive natural products from sponge-associated actinomycetes Usama Ramadan Abdelmohsen,		
14.00	Bioactive natural products from sponge-associated actinomycetes Usama Ramadan Abdelmohsen, Würzburg Structure elucidation and total synthesis of bioactive natural products		
14.00	Bioactive natural products from sponge-associated actinomycetes Usama Ramadan Abdelmohsen, Würzburg  Structure elucidation and total synthesis of bioactive natural products Till Opatz, Mainz  Who guards the guardians - New role for (matrix)-metalloproteinases in the context of immunologic regulation		
14.00 14.25 14.50	Bioactive natural products from sponge-associated actinomycetes Usama Ramadan Abdelmohsen, Würzburg  Structure elucidation and total synthesis of bioactive natural products Till Opatz, Mainz  Who guards the guardians - New role for (matrix)-metalloproteinases in the context of immunologic regulation Sven Fridrich, Mainz  Taspase 1: A protease with still unresolved depth		

### Lageplan

Universitätsmedizin Mainz



Geb. 102/ EG H1-404, großer Hörsaal der HNO-Klinik

#### Universitätsmedizin

der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131 Mainz

Auf unserer Homepage www.unimedizin-mainz.de finden Sie Anfahrtsskizzen sowie mögliche Busverbindungen.



# **ChemBioMed III - Disease Relevant Proteases**

## **Ligands from Nature and from Rational Design**

Unser Wissen für Ihre Gesundheit



December 13 & 14, 2013

## **ChemBioMed III - Disease Relevant Proteases**

### Dear colleagues,

proteases play critical roles in numerous physiological and pathological conditions, including inflammation, viral infections, blood clotting disorders, neurological diseases, and cancer. Therefore, proteases are not only of academic and clinical interest, but also important drug targets for the pharmaceutical industry.

In this respect, natural products have been a source for important drugs for many years. Albeit their chemical complexity poses significant challenges regarding synthesis, it is this complexity, which also confers unique biological properties. To more successfully exploit this reservoir in the future interdisciplinary collaborations are needed.

Consequently, we invited a number of excellent speakers who will present lectures covering innovative targets, assay development and screening technologies and new compounds with activity in pre-clinical models or early clinical trials. The meeting addresses researchers from different scientific areas - medicine, chemistry, pharmacology, biology, chemoinformatics - sharing an interest in the interdisciplinary field of protease research and "Chemical BioMedicine".

We hope that as in our past symposiums, we will be able to bridge the gap between basic research and clinical application.

We are very happy to invite you to join us in Mainz for our transdisciplinary symposium.

With best regards,

Tanja Schirmeister, Roland Stauber, Walter Stöcker

Friday, December 13th		16.20	Functional and structural
12.00	Welcome-Lunch		constraints involved in coronavirus 3C-like protease-mediated polyprotein processing
13.00	<b>Welcome</b> Roland Stauber	44.45	John Ziebuhr, Gießen
13.15	Systems pharmacology: An integration of cell and	16.45	Medicinal chemistry of dengue virus protease Christian Klein, Heidelberg
	computational biology for drug discovery Eugenio Fava, Bonn	17.10	Phosphinic peptide inhibitors as tools to probe zinc-metalloprotease function:
13.40	New ways to inhibit enzymes by protein surface binding - A case study with ß-tryptase		Past and future Vincent Dive, Paris
14.05	Carsten Schmuck, Duisburg-Essen  Azapeptide nitriles as inhibitors of human cathepsins  Michael Gütschow, Bonn	19.00	Excursion and dinner Kupferbergterrassen
14.30	European lead factory: An open innovation approach to drug	Saturday, December 14	
	discovery Dimitrios Tzalis, Dortmund	09.15	Exploiting nature's rich source of proteasome inhibitors as starting points in drug development  Michael Groll, München
15.00	Coffee break	09.40	Potent and specific peptide
15.30	Myxobacteria - Natural compounds, mechanisms,		inhibitors of human matriptase by design and evolution Harald Kolmar, Darmstadt
	enzymes Carsten Volz, Saarbrücken	10.05	Regulation of foamy virus protease by viral RNA-Gag p71/p68
15.55	Fungal secondary metabolites - Highly diverse compounds as lead structures in pharma and		cleavage is required for template switch of reverse transcriptase Jochen Bodem, Würzburg
	agrochemical research Eckardt Thines, Mainz	10.30	Argyrin F- A new type of proteasome inhibitor for the treatment of solid tumors Nisar Malek, Tübingen